Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Jessica Merrill
The company is the latest big pharma to announce clinical trial delays due to the COVID-19 pandemic and has postponed an R&D day, but it also delivered the message that supply and commercial operations appear on track.
Biogen confirmed that some patients treated with Spinraza are temporarily having their dosing postponed as hospital systems brace for COVID-19, potentially a broader issue for the industry.
Sage will initiate three new trials to support FDA approval of the drug for post-partum depression and major depressive disorder, with data anticipated in 2021.
Industry is limiting face-to-face interactions between sales reps and physicians, and some patients are sitting out visits, amid the COVID-19 outbreak. That poses big business challenges for pharma.
The Phase II/III trial will begin enrolling patients in the US immediately, with Regeneron taking the lead in US development and Sanofi leading ex-US trials.
Autoimmune disease drugs ranging from Humira to Cosentyx to Tremfya to Xeljanz carry warnings about increased risk of infections. This raises new questions in the novel coronavirus outbreak.